The estimated Net Worth of Terrence C Kearney is at least $18.9 Milion dollars as of 10 August 2023. Mr. Kearney owns over 10,000 units of Vertex Pharmaceuticals stock worth over $7,850,301 and over the last 14 years he sold VRTX stock worth over $10,489,600. In addition, he makes $542,603 as Independent Director at Vertex Pharmaceuticals.
Terrence has made over 5 trades of the Vertex Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of VRTX stock worth $1,275,400 on 10 August 2023.
The largest trade he's ever made was exercising 68,125 units of Vertex Pharmaceuticals stock on 27 April 2015 worth over $3,870,863. On average, Terrence trades about 5,139 units every 92 days since 2011. As of 10 August 2023 he still owns at least 16,536 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Kearney stock trades at the bottom of the page.
Terrence C. Kearney is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Kearney served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication delivery company, from April 2006 to January 2011. From April 2004 to April 2006, he served as Hospira’s Senior Vice President, Finance, and Chief Financial Officer, and he served as Acting Chief Financial Officer through August 2006. Mr. Kearney served as Vice President and Treasurer of Abbott Laboratories from 2001 to April 2004. From 1996 to 2001, Mr. Kearney was Divisional Vice President and Controller for Abbott’s International Division. Mr. Kearney serves as a member of the Board of Directors at Acceleron Pharma Inc., a biopharmaceutical company. He served as a member of the Board of Directors of Innovia (formerly known as Theravance, Inc.), a royalty management company, from October 2014 through April 2016, and as member of the Board of Directors of AveXis, Inc., a gene therapy company, from January 2016 until its acquisition in May 2018. Mr. Kearney has been a member of the Board of Directors of Levo Therapeutics, Inc., a biotechnology company focused on developing treatments for Prader-Willi Syndrome, since 2018. He received his B.S. in biology from the University of Illinois and his M.B.A. from the University of Denver.
As the Independent Director of Vertex Pharmaceuticals, the total compensation of Terrence Kearney at Vertex Pharmaceuticals is $542,603. There are 15 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
Terrence Kearney is 65, he's been the Independent Director of Vertex Pharmaceuticals since 2011. There are 1 older and 22 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Terrence's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden oraz Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: